Consensus Elevance Health, Inc.

Equities

ELV

US0367521038

Market Closed - Nyse 04:00:01 2024-03-28 pm EDT 5-day change 1st Jan Change
518.5 USD -0.27% Intraday chart for Elevance Health, Inc. +0.75% +9.96%

Evolution of the average Target Price on Elevance Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dfc7a29e5f6b9dd4db1.ssCPo13A13nwobBPvpxR2ji39RsiMIBTdw6p6KXAM4A._YSi5wmikQ68zsIg8f8HnRXHullgceomM2buscK3VMrtre3vO_OTI7bO_Q~b446cd9df1236d2b3f27c5240e60299c
Barclays Starts Elevance Health With Overweight Rating, $584 Price Target MT
Cantor Fitzgerald Adjusts Price Target on Elevance Health to $580 From $547, Maintains Overweight Rating MT
US proposes reimbursement rate for Medicare Advantage 2025 payments RE
RBC Raises Price Target on Elevance Health to $574 From $572 Amid 'Solid End to 2023,' Keeps Outperform Rating MT
JPMorgan Cuts Price Target on Elevance Health to $552 From $569, Maintains Overweight Rating MT
Investors see life through rose-colored glasses Our Logo
ANALYST RECOMMENDATIONS : Air Products & Chemicals, Barclays, Glencore, Mastercard, Walmart... Our Logo
Central bank bonanza! Our Logo
ANALYST RECOMMENDATIONS : AbbVie, AMD, Astrazeneca, HSBC, Live Nation... Our Logo
Nephron Research Adjusts Price Target on Elevance Health to $500 From $493, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Elevance Health to $572 From $558, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Elevance Health to $587 From $585, Maintains Overweight Rating MT
Deutsche Bank Adjusts Elevance Health Price Target to $558 From $580, Maintains Buy Rating MT
Morgan Stanley Boosts Price Target on Elevance Health to $585 From $571, Names Stock 'Top Pick,' Keeps Overweight Rating MT
TD Cowen Raises Elevance Health's Price Target to $585 From $564, Outperform Rating Kept MT
Deutsche Bank Adjusts Elevance Health Price Target to $580 From $575, Maintains Buy Rating MT
UBS Adjusts Elevance Health Price Target to $585 From $575, Maintains Buy Rating MT
UBS Adjusts Elevance Health Price Target to $575 From $610, Maintains Buy Rating MT
Jefferies Adjusts Elevance Health's Price Target to $537 From $558, Keeps Buy Rating MT
Wolfe Research Downgrades Elevance Health to Peer Perform From Outperform MT
JPMorgan Adjusts Price Target on Elevance Health to $535 From $572, Maintains Overweight Rating MT
Truist Securities Cuts Price Target on Elevance Health to $560 From $580, Maintains Buy Rating MT
Equity Markets Mostly Higher Ahead of Fed Rate Decision MT
Morgan Stanley Upgrades Elevance Health to Overweight From Equalweight, Adjusts Price Target to $571 From $500 MT
Wells Fargo Adjusts Price Target on Elevance Health to $561 From $597, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
518.5 USD
Average target price
574.4 USD
Spread / Average Target
+10.77%
High Price Target
629 USD
Spread / Highest target
+21.30%
Low Price Target
520 USD
Spread / Lowest Target
+0.28%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Elevance Health, Inc.

Barclays
Cantor Fitzgerald
RBC Capital Markets
JPMorgan Chase
Nephron Research
Goldman Sachs
Morgan Stanley
Deutsche Bank Securities
TD Cowen
UBS
Jefferies & Co.
Wolfe Research
Truist Securities
Wells Fargo Securities
Loop Capital
Morningstar
SVB Securities LLC
Credit Suisse
Mizuho Securities
BofA Securities
Bernstein
Cowen
SVB Leerink
Argus
BMO Capital
Stephens Inc.
Seaport Global Securities
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings